1. Home
  2. ALLT vs PRTC Comparison

ALLT vs PRTC Comparison

Compare ALLT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$9.86

Market Cap

429.1M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
PRTC
Founded
1996
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
429.1M
386.7M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ALLT
PRTC
Price
$9.86
$16.91
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$12.75
N/A
AVG Volume (30 Days)
455.0K
4.8K
Earning Date
11-20-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
0.20
Revenue
$98,512,000.00
$6,391,000.00
Revenue This Year
$12.44
N/A
Revenue Next Year
$12.98
N/A
P/E Ratio
$457.61
$7.77
Revenue Growth
7.51
1265.60
52 Week Low
$4.37
$13.30
52 Week High
$11.42
$23.35

Technical Indicators

Market Signals
Indicator
ALLT
PRTC
Relative Strength Index (RSI) 55.96 51.09
Support Level $9.68 $16.44
Resistance Level $10.35 $17.17
Average True Range (ATR) 0.39 0.35
MACD 0.10 0.12
Stochastic Oscillator 62.50 55.29

Price Performance

Historical Comparison
ALLT
PRTC

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: